Phase 1, Open-Label, Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma

Trial Profile

Phase 1, Open-Label, Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Aug 2017

At a glance

  • Drugs CLR 1404 I-131 (Primary) ; Dexamethasone
  • Indications Multiple myeloma
  • Focus Adverse reactions; Proof of concept
  • Sponsors Cellectar Biosciences
  • Most Recent Events

    • 08 Aug 2017 Data published in a Cellectar Biosciences Media Release.
    • 08 Aug 2017 According to a Cellectar Biosciences media release, company continues to collect overall survival data on all evaluable trial participants and will provide timely updates, as appropriate.
    • 08 Aug 2017 According to a Cellectar Biosciences media release, fourth cohort of this trial is fully enrolled, initial results from this cohort is expected by the close of the third quarter 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top